Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dexcom Inc (NQ: DXCM )

138.01 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 654
Open 138.01
Bid (Size) 130.75 (2)
Ask (Size) 132.90 (1)
Prev. Close 138.01
Today's Range 138.01 - 138.01
52wk Range 74.75 - 142.00
Shares Outstanding 96,748,901
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Intel Reports Weak Sales, Joins Boyd Gaming, Atlassian And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
DexCom (DXCM) Q1 2024 Earnings Call Transcript
DXCM earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial

Performance

YTD
+12.12%
+12.12%
1 Month
-1.37%
-1.37%
3 Month
+9.09%
+9.09%
6 Month
+70.19%
+70.19%
1 Year
+10.47%
+10.47%

More News

Read More
DXCM Stock Earnings: DexCom Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Peering Into DexCom's Recent Short Interest
Via Benzinga
Dexcom Beats First-Quarter Views And Raises Sales Outlook, But Shares Crumble
Via Investor's Business Daily
$1000 Invested In DexCom 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Why NASDAQ:DXCM Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
The Analyst Verdict: DexCom In The Eyes Of 4 Experts
Via Benzinga
Dexcom Reports First Quarter 2024 Financial Results
From DexCom, Inc.
Via Business Wire
Staar Surgical Stock Climbs The Leadership Ladder With Jump To 84 RS Rating
Via Investor's Business Daily
3 Innovative Stocks to Buy Before Earnings Amid the Market Pullback
Via Talk Markets
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
Via Investor's Business Daily
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Via InvestorPlace
Topics ETFs
Disruptive Forces: 3 Game-changing Stocks Reshaping the Tech Landscape
Via InvestorPlace
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
Via Investor's Business Daily
Nasdaq Nightmares: 3 Stocks to Sell Before Reality Sets In
Via InvestorPlace
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
Via InvestorPlace
DexCom Stock Sees IBD Stock Market Rating Sweetens Ups; Earns 83 RS Rating
Via Investor's Business Daily
2 Growth Stocks to Buy Hand Over Fist in April
Via The Motley Fool
7 Nasdaq Stocks to Sell in April Before They Crash & Burn
Via InvestorPlace
Dexcom Publishes Annual Sustainability Report
From DexCom, Inc.
Via Business Wire
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
DexCom Stock Gains from GLP-1 Diabetic Users
Via MarketBeat
3 Overvalued S&P 500 Stocks for Your ‘Do NOT Buy’ List
Via InvestorPlace
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.